RE:RE:RE:RE:RE:RE:RE:RE:Quick look at Biotoscana's competitor Q1 resultIf only and when the following from GBT website would be properly explianed in dettails by the takeover company? we would know if holding GUD makes sense. Biotech is sll about new drug pipeline. If after the takeover I am still in the dar than good by.
GBT has long-standing partnerships with global leaders of the quality and prestige of Basilea Pharmaceutica®, Biocad®, Celgene Corporation®, CSL Behring®, Dr. Falk Pharma®, Grupo Ferrer®, Gilead Sciences®, Leadiant Biosciences®, Pierre-Fabre Medicament® and Pint Pharma®. Our strong team of scientists and business development people tap permanently into the world’s innovation centers and into the region’s most knowledgeable physicians to evaluate hundreds of possible collaborations annually. At the same time, GBT has a proprietary team of more than 80 people fully dedicated the discovery, development and registration of new products, working on one of the most advanced research and development centers in the region. A very disciplined approach allows us to understand the most advanced research trends and determine which products will be more appropriate for the region and decide which to develop in-house and which are better candidates for collaboration. Combining all its rich ecosystem, GBT currently has more than 50 research programs in different phases of development and some 150 molecules in commercial stage.